Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...
Registry analysis of 36,148 relapsing-onset cases showed lower annual DMT treatment probability in late-onset versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results